Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.45    0.00 (0.00%)
Bid:
8.30
Ask:
8.60
Spread: 0.30 (3.614%)
Market Cap: £18.43m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Nov 20127:00 amRNSPreliminary Results
9th Nov 20121:32 pmRNSNotice of Results
5th Nov 20121:00 pmRNSBlocklisting Interim Review
17th Oct 20125:27 pmRNSBlocklisting Interim Review
1st Oct 201211:44 amRNSTotal Voting Rights
26th Sep 20127:00 amRNSHolding(s) in Company
31st Aug 20124:40 pmRNSSecond Price Monitoring Extn
31st Aug 20124:35 pmRNSPrice Monitoring Extension
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
16th Aug 20127:00 amRNSInterim Management Statement
18th Jun 20129:59 amRNSBlocklisting Interim Review
30th May 20127:00 amRNSHalf Yearly Report
11th May 20127:00 amRNSResearch Update
3rd May 201211:46 amRNSNotice of Results
3rd May 20129:54 amRNSBlocklisting Interim Review
18th Apr 20127:00 amRNSResearch Update
18th Apr 20127:00 amRNSResearch Update
11th Apr 201211:08 amRNSBlock Listing Application
29th Mar 20127:00 amRNSDirectorate Change
28th Mar 20129:35 amRNSResult of AGM
24th Feb 20127:00 amRNSNotice of AGM
16th Feb 20127:00 amRNSInterim Management Statement
14th Feb 20129:34 amRNSHolding(s) in Company
6th Feb 20129:25 amRNSAnnual Information Update
2nd Feb 20127:00 amRNSDirectorate Change
27th Jan 201210:17 amRNSAnnual Financial Report
16th Jan 20127:00 amRNSResearch Update
11th Jan 20123:53 pmRNSBlocklisting Interim Cancellation
3rd Jan 201212:00 pmRNSBlocklisting Interim Review
28th Nov 201110:09 amRNSDirector/PDMR Shareholding
28th Nov 201110:08 amRNSDirector/PDMR Shareholding
24th Nov 20117:00 amRNSFinal Results
7th Nov 20118:51 amRNSBlocklisting Interim Review
4th Oct 20117:00 amRNSResearch Update
29th Sep 20117:00 amRNSResearch Update
16th Aug 20117:00 amRNSInterim Management Statement
28th Jul 20117:31 amRNSResearch Update
12th Jul 201112:04 pmRNSBlocklisting Interim Review
5th Jul 201112:04 pmRNSTotal Voting Rights
17th Jun 20113:28 pmRNSBlocklisting Interim Review
26th May 20117:00 amRNSHalf Yearly Report
17th May 20118:35 amRNSNotice of Results
5th May 20117:00 amRNSBlocklisting Interim Review
31st Mar 20119:07 amRNSResult of AGM
2nd Mar 201112:27 pmRNSHolding(s) in Company
15th Feb 20117:00 amRNSInterim Management Statement
7th Feb 201112:18 pmRNSAnnual Information Update
1st Feb 20118:54 amRNSTotal Voting Rights
1st Feb 20118:53 amRNSAnnual Financial Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.